The first dual orexin receptor antagonist for double appetite insomnia in China has officially been launched.

On August 16, Wei Cai announced the official launch of the innovative drug Lai Bolesheng in China. This product is the first dual orexin receptor antagonist approved in China for the treatment of adult insomnia characterized by difficulty falling asleep and/or difficulty maintaining sleep. At the same time, Wei Cai China has reached a strategic cooperation with JD Health. Lai Bolesheng has been exclusively launched on JD Health's B2C and O2O channels.